entertainment -WSS

entertainment

author：focus 2025-09-30 00:05:08 - browse：9

The FDA building -- First Opinion coverage from STAT — Adobe

U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people to grow bone where it otherwise shouldn’t be, extending an option to patients who have been advocating for access to the medicine.

The treatment, an oral medication that will be marketed as Sohonos, faced some questions about the quality of its data, and was rejected earlier this year by European regulators. But in approving the drug for the treatment of fibrodysplasia ossificans progressiva, or FOP, the Food and Drug Administration concluded that Sohonos’ benefits outweigh its risks.

“I just closed my eyes and looked up to the skies, like ‘Thank you, God,’” said Suzanne Hollywood, whose teenage son, Joey, has been receiving the drug in a clinical trial. “It’s far from perfect, but I’m thrilled for my son, for his future, and for the kids getting diagnosed who might not have to experience what others had to.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Mayo Clinic plans $5B tech

hotspot

WSS

FDA investigates CAR

BIO selects John Crowley as new CEO

The Biogen Aduhelm mess could happen again

Flagship Pioneering launches a new biotech in two countries

Devoted Health’s losses in Medicare Advantage persist

A protest over insulin prices is seen as a fight for life

knowledge

entertainment

focus

Drug repurposing or repositioning? The language matters

Surgery pushed Ben Carson to fame

Activists slam private health insurers over coverage restrictions

Medicare Advantage plans can’t deny care with AI, CMS warns

Guidelines to prevent youth baseball injuries need more muscle

CDC director unscathed in first congressional testimony

Jerome Adams on the need for new antivirals for Covid

Will the market for weight loss drugs really reach $100 billion?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ReNAgade cuts staff seven months after raising $300 million

hotspot

Cigna, Humana reportedly in talks to merge

BIO selects John Crowley as new CEO

Gene therapy for Afghan refugees’ infant will be fully covered

Despite FDA concern, risk that CAR

BIO selects John Crowley as new CEO

UnitedHealth’s Optum accused of antitrust violations in California

hotspot

Wikipedia

focus

knowledge